EVM
BEAM icon

Eaton Vance Management’s Beam Therapeutics BEAM Stock Holding History

Eaton Vance Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-141
Closed -$11K – 2823
2021
Q1 		$11K Buy
+141
New +$13.4K ﹤0.01% 2315

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eaton Vance Management's BEAM Position: Q2 2021 in Review

Eaton Vance Management sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 141 shares — an estimated $11K sold.

Eaton Vance Management first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $11K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Eaton Vance Management reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 141 Beam Therapeutics shares in Q2 2021, an estimated $11K.
  • Eaton Vance Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Beam Therapeutics position peaked at $11K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.